Welcome to our dedicated page for Revance Therapeu news (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeu stock.
The RVNC news page on Stock Titan provides an archive of announcements and transaction-related communications concerning Revance Therapeutics, Inc., a biotechnology company focused on aesthetic and therapeutic offerings. These news items document Revance’s role in the aesthetic injectables market, its product portfolio, and the corporate events that led to its acquisition by Crown Laboratories, Inc.
Readers can review press releases describing Crown’s commencement of a cash tender offer to acquire all outstanding shares of Revance, subsequent extensions of the tender offer, and an increase in the offer price that was unanimously approved by the Revance Board of Directors. Additional news items cover competing interest from Teoxane SA, reminders to Revance stockholders about tendering their shares, and joint announcements by Crown and Revance regarding the expiration of the tender offer and satisfaction of its conditions.
The archive also includes Crown’s announcements of the successful closing of the acquisition and completion of the second-step merger, in which Crown stated that Revance’s common stock will be delisted from the NASDAQ Global Select Market and deregistered. These releases provide context on how Revance, as the issuer of RVNC, transitioned from an independent publicly traded biotechnology company to a Crown-owned business within a larger skincare and aesthetics platform.
For investors and researchers, the RVNC news feed serves as a historical record of key milestones, including strategic reviews by the Revance Board, tender offer mechanics, and the ultimate outcome of the Crown transaction. Users interested in the evolution of Revance’s aesthetic and therapeutic portfolio, its partnerships with Teoxane SA, Viatris Inc., and Shanghai Fosun Pharmaceutical, and the terms of the acquisition can use this page to trace the sequence of public communications around the deal.
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced that the FDA will initiate a pre-approval inspection of its manufacturing facility for DaxibotulinumtoxinA for Injection by the end of June 2021. This follows a deferral from the FDA in November 2020 due to COVID-19 travel restrictions affecting inspection completion. Revance's DaxibotulinumtoxinA is advanced for treating glabellar lines and is currently in a Phase 3 program. Revance is also developing a biosimilar to BOTOX® in partnership with Viatris.
Revance Therapeutics, Inc. (Nasdaq: RVNC) reported a first quarter 2021 revenue of $13.3 million, a significant increase from $0.1 million in Q1 2020, driven primarily by the RHA® Collection of dermal fillers. However, the company faced a net loss of $71.6 million. SG&A expenses rose to $49.0 million, while R&D expenses decreased to $27.3 million. Cash equivalents stood at $386.8 million, and the company raised $21.7 million from its ATM program. The FDA's review of DaxibotulinumtoxinA for Injection remains pending due to inspection scheduling delays.
Revance Therapeutics, Inc. (Nasdaq: RVNC) will release its first quarter 2021 financial results on May 10, 2021, after market close. A conference call and live webcast discussing these results will take place at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Revance is known for its neuromodulator product, DaxibotulinumtoxinA for Injection, which has completed Phase 3 trials and is awaiting U.S. regulatory approval. The company also holds exclusive U.S. distribution rights for RHA® Collection dermal fillers and is developing a biosimilar to BOTOX® in partnership with Viatris.
Revance Therapeutics (Nasdaq: RVNC) announced a presentation at The American Society for Aesthetic Plastic Surgery Aesthetic Meeting 2021, highlighting data from the Phase 3 SAKURA clinical program. This analysis demonstrated the efficacy, safety, and duration of DaxibotulinumtoxinA for Injection in treating glabellar lines across various female age groups. With over 3,000 subjects, the data confirmed a median time to loss of none or mild symptoms lasting at least 24 weeks. Revance is seeking FDA approval for this treatment, aiming to transform patient experiences in the aesthetic and therapeutic markets.
Revance Therapeutics (Nasdaq: RVNC) has announced the initiation of Phase 3 trials for DaxibotulinumtoxinA in China, aimed at treating glabellar lines and cervical dystonia. The first patients were dosed in April 2023. The Chinese market for neuromodulators is rapidly growing, projected to expand from $318 million in 2021 to $762 million by 2027. Revance has a licensing agreement with Fosun Pharma, which includes potential milestone payments of $230 million and royalties based on future sales.
Revance Therapeutics has announced it will present four ePoster abstracts at the AAD VMX meeting from April 23-25, 2021. These presentations include new data from the SAKURA Phase 3 program for DaxibotulinumtoxinA for Injection, highlighting its effectiveness in eliminating glabellar lines. The abstracts also feature subgroup analysis of efficacy among adult females and the impact of hyaluronic acid filler manufacturing on HA chain degradation. Attendees can access sessions on-demand until July 12, 2021, via the AAD website.
Revance Therapeutics, Inc. (Nasdaq: RVNC) will participate in the 20th Annual Needham Virtual Healthcare Conference from April 12-15. CEO Mark Foley is scheduled for a fireside chat on April 13 at 7:15 a.m. PT / 10:15 a.m. ET. Interested parties can access the live audio webcast via the Investor Relations section on www.revance.com. The conference will feature the company's innovative products, including DaxibotulinumtoxinA for Injection, a next-generation neuromodulator targeting various aesthetic and therapeutic applications.
Revance Therapeutics (Nasdaq: RVNC) will present an ePoster at the 2021 American Academy of Neurology Annual Meeting, showcasing results from the ASPEN-1 Phase 3 trial of DaxibotulinumtoxinA for Injection, targeting cervical dystonia. The trial demonstrated a median treatment effect duration of up to 24 weeks, suggesting a potential 50% reduction in annual treatment frequency. The FDA previously granted orphan drug designation for this treatment, indicating significant developmental support.
Summary not available.
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced that CEO Mark Foley will participate in fireside chats at two major virtual healthcare conferences. The first is the Cowen 41st Annual Virtual Healthcare Conference on March 3, 2021, followed by the Barclays Global Healthcare Conference on March 9, 2021. Interested parties can listen to the live audio webcast through the Investor Relations section of Revance's website, with a replay available for 30 days post-conference. Revance focuses on innovative aesthetic and therapeutic products, including its neuromodulator, DaxibotulinumtoxinA.